DOSSIER · 13F-HR · Q2 2026

Merck & Co., Inc.

$526M in tracked AUM across 13 positions as of Q2 2026.

M&
CIK 0000310158 · last filed Jun 30, 2026
Total AUM
$526M
as of Q2 2026
Holdings
13
positions
Whale Score
75
75
strong
Activity
no data
changes this Q
AI Analysis · Q2 2026

Portfolio Overview

The filing for Merck & Co., Inc. (CIK: 0000310158) reveals a highly specialized, non-diversified investment portfolio with a distinct focus on the biotechnology sector. As of the reporting period ending September 30, 2025, the total portfolio value stood at approximately $171.31 million, spread across just 8 holdings. This represents a significant contraction in capital, with the portfolio value decreasing by 20.5% from the previous quarter's $215.60 million. ...

The portfolio exhibits an extremely high concentration profile, lacking traditional diversification across broad sectors or asset classes. The top two holdings alone account for 88.25% of the total assets, with the largest position representing over half of the portfolio's value. This structure suggests that the portfolio is not managed for general market exposure but rather for specific, strategic outcomes likely related to corporate development or venture-style investments.

Key Holdings

Analysis generated by 13F Insight from SEC Form 13F filing data · Q2 2026. Methodology

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
PSNL
PERSONALIS INC
$188M14.0M35.8%
02
MRNA
MODERNA INC
$162M2.3M30.7%
03
KYMR
KYMERA THERAPEUTICS INC
$89M772K16.8%
04
AKTS
AKTIS ONCOLOGY INC
$31M953K5.8%
05
EIKN
EIKON THERAPEUTICS INC
$22M1.7M4.1%
06
TRDA
ENTRADA THERAPEUTICS INC
$13M1.7M2.4%
07
STRO
SUTRO BIOPHARMA INC
$9M272K1.7%
08
ALEC
ALECTOR INC
$7M3.5M1.4%
09
EVAX
EVAXION BIOTECH A/S
$4M1.2M0.7%
10
VRDN
VIRIDIAN THERAPEUTICS INC
$2M93K0.3%

Filing history

2026Q2Jun 30
$526M 50.6%
13 positionsView →
2026Q1Mar 31
$349M 26.5%
14 positionsView →
2025Q4Dec 31
$276M 61.3%
12 positionsView →
2025Q3Sep 30
$171M 20.5%
8 positionsView →
2025Q2Jun 30
$216M 31.2%
13 positionsLocked
2025Q1Mar 31
$164M 36.3%
12 positionsLocked
2024Q4Dec 31
$258M
13 positionsLocked